Literature DB >> 17541528

[Blood glucose control in type 2 diabetes. Basic requirements for reducing vascular complications].

J Seissler1.   

Abstract

Patients with type 2 diabetes are at high risk for the development of micro- and macrovascular complications. It is necessary to aim at an early, multifactorial intervention at different levels of metabolic syndrome. Epidemiological data have consistently shown that postprandial hyperglycaemia has strong proatherogenic effects, increasing overall cardiovascular risk. These findings indicate that intensive blood glucose control with the aim of maintaining near normal preprandial (<110 mg/dl) and postprandial levels (<140 mg/dl) is required to minimise the incidence of complications. Antidiabetic therapy should be selected individually by integrating therapeutic goals and the patient's possibilities for self-management. The fact that national recommendations for the treatment of patients with type 2 diabetes are not fully implemented in clinical practice emphasizes the importance of further activities to improve the quality of care.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541528     DOI: 10.1007/s00108-007-1877-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

1.  [National guideline for diabetes mellitus type 2, abridged version. May 2002. Federal Chamber of Physicians].

Authors: 
Journal:  Z Arztl Fortbild Qualitatssich       Date:  2002-07

2.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  [Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care].

Authors:  David Pittrow; Günther Karl Stalla; Andreas M Zeiher; Sigmund Silber; Winfried März; Lars Pieper; Jens Klotsche; Heide Glaesmer; Günther Ruf; Harald Jörn Schneider; Hendrik Lehnert; Steffen Böhler; Uwe Koch; Hans-Ulrich Wittchen
Journal:  Med Klin (Munich)       Date:  2006-08-15

4.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.

Authors:  M Hanefeld; S Fischer; U Julius; J Schulze; U Schwanebeck; H Schmechel; H J Ziegelasch; J Lindner
Journal:  Diabetologia       Date:  1996-12       Impact factor: 10.122

5.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.

Authors:  M Coutinho; H C Gerstein; Y Wang; S Yusuf
Journal:  Diabetes Care       Date:  1999-02       Impact factor: 19.112

6.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

Authors: 
Journal:  Arch Intern Med       Date:  2001-02-12

7.  Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.

Authors:  David M Nathan; John Lachin; Patricia Cleary; Trevor Orchard; David J Brillon; Jye-Yu Backlund; Daniel H O'Leary; Saul Genuth
Journal:  N Engl J Med       Date:  2003-06-05       Impact factor: 91.245

8.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

9.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

10.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.